Insulet Corporation (PODD) has rebounded to about $331/share after a volatile stretch. Demand for wearable insulin technology continues to rise, margins are improving, and the company’s recurring revenue engine remains one of its biggest advantages. Analysts now see a clearer growth path through 2027 as execution improves.
Recently, Insulet reported stronger momentum in its Omnipod franchise, supported by healthier new patient adoption and improved manufacturing efficiency. The company also expanded its Omnipod 5 platform, which helped drive better engagement in both the United States and international markets. These developments suggest Insulet can still accelerate growth while navigating a competitive med tech landscape.
This article looks at where Wall Street analysts think Insulet could trade by 2027. We pulled together consensus price targets and TIKR’s valuation model to outline the stock’s potential path. These figures reflect current analyst expectations and are not TIKR’s own predictions.
Find out what a stock’s really worth in under 60 seconds with TIKR’s new Valuation Model (It’s free) >>>
Analyst Price Targets Suggest Moderate Upside
Insulet trades around $331/share, and the latest analyst price targets point to an average of about $376/share. That represents roughly 14% upside, which places the stock in the moderate upside category. Analysts expect gains, but not a major rerating unless performance exceeds expectations.
Street Targets (11/21/25):
- Median target: $380/share
- High estimate: $428/share
- Low estimate: $314/share
- Ratings: 18 Buys, 5 Outperforms, 2 Holds
For investors, the takeaway is clear. Analysts see steady room for the stock to move higher, supported by improving fundamentals and a strong recurring revenue base. The tight range between the high and low targets shows broad agreement on Insulet’s long term trajectory.
Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
Insulet Growth Outlook and Valuation
The company’s outlook appears strong based on the key inputs shown in the Guided Valuation Model:
- Revenue growth forecast of 23.1% through 2027
- Operating margins expected to reach 19.0%
- Shares valued at 57.6x forward earnings in the model
- Based on analysts’ average estimates, TIKR’s Guided Valuation Model using a 57.6x forward P E suggests about $530/share by 12/31/27
- That implies 60.2% total upside, or roughly 25% annualized returns
These model assumptions point to steady and high quality compounding. For investors, the takeaway is clear. Strong revenue growth, a healthier margin profile, and a premium valuation supported by recurring revenue all contribute to a long runway for returns. The forecast does not rely on extreme acceleration, only consistent execution.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
What’s Driving the Optimism?
Analysts remain optimistic because Insulet continues to show strong traction in its Omnipod franchise. Patient adoption trends have been healthy, and recurring pod orders provide dependable revenue. Improvements in manufacturing are also helping support stronger margins and giving the company more financial flexibility.
Management’s efforts to expand the Omnipod 5 platform and grow internationally are also driving sentiment. Early traction outside the United States suggests a significant opportunity ahead. For investors, these strengths point to a business with staying power and durable competitive advantages.
Bear Case: Valuation and Competitive Pressure
Even with these positives, valuation remains a key consideration. Insulet trades at a premium, which means consistent execution is required to support the stock’s current level. Any slowdown in patient adoption or recurring pod usage could lead to weaker returns.
Competition also remains a factor. Companies in the diabetes technology space continue to improve their platforms, and Insulet must maintain its lead in ease of use and product reliability. For investors, the risk is tied to whether Insulet can sustain its leadership while operating at a premium valuation.
Outlook for 2027: What Could Insulet Be Worth?
Based on analysts’ average estimates, TIKR’s Guided Valuation Model suggests Insulet could reach about $530/share by the end of 2027. That represents roughly 60% upside from today, or about 25% annualized returns.
These expectations already assume steady execution and continued growth in the Omnipod platform. To deliver stronger returns, Insulet would need faster international expansion or better than expected operating leverage. Without that, investors should expect healthy and dependable compounding.
For investors, Insulet appears well positioned as a long term compounder with meaningful upside potential. The stock’s foundation is supported by solid fundamentals and a recurring revenue business that benefits from rising demand for wearable insulin delivery systems.
AI Compounders With Massive Upside That Wall Street Is Overlooking
Everyone wants to cash in on AI. But while the crowd chases the obvious names benefiting from AI like NVIDIA, AMD, or Taiwan Semiconductor, the real opportunity may lie on the AI application layer where a handful of compounders are quietly embedding AI into products people already use every day.
TIKR just released a new free report on 5 undervalued compounders that analysts believe could deliver years of outperformance as AI adoption accelerates.
Inside the report, you’ll find:
- Businesses already turning AI into revenue and earnings growth
- Stocks trading below fair value despite strong analyst forecasts
- Unique picks most investors haven’t even considered
If you want to catch the next wave of AI winners, this report is a must-read.
Find out what your favorite stocks are really worth (Free with TIKR) >>>
